GlobeNewswire: Alaunos Therapeutics, Inc. Contains the last 10 of 329 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:39:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/11/14/2779968/0/en/Alaunos-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-Phase-1-Clinical-Data-and-Continued-Exploration-of-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives2023-11-14T12:30:00Z<![CDATA[HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic advisor. Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.]]>Best Response to TCR-TBest Response to TCR-Thttps://www.globenewswire.com/news-release/2023/08/14/2725008/0/en/Alaunos-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-Interim-Clinical-Data-and-Exploration-of-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives2023-08-14T20:05:34Z<![CDATA[HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic reprioritization to focus on its hunTR® TCR discovery platform, wind down its TCR-T Phase 1/2 Library trial and explore broad strategic alternatives for the Company. Alaunos is implementing a cost-savings plan that includes a reduction in workforce by approximately 60%.]]>https://www.globenewswire.com/news-release/2023/06/29/2696871/0/en/Alaunos-Therapeutics-Announces-Presentation-at-the-2nd-Hawaii-Global-Summit-on-Thoracic-Malignancies.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies2023-06-29T11:00:53Z<![CDATA[HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023.]]>https://www.globenewswire.com/news-release/2023/05/25/2676766/0/en/Alaunos-Therapeutics-to-Present-Early-Data-from-TCR-T-Library-Phase-1-2-Trial-at-2023-American-Society-of-Clinical-Oncology-Annual-Meeting.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting 2023-05-25T21:00:52Z<![CDATA[HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.]]>https://www.globenewswire.com/news-release/2023/05/10/2665401/0/en/Alaunos-Therapeutics-Reports-First-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Reports First Quarter 2023 Financial Results2023-05-10T11:00:17Z<![CDATA[HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2023/05/03/2660347/0/en/Alaunos-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-on-May-10-2023.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 20232023-05-03T12:30:00Z<![CDATA[HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2023/04/26/2655475/0/en/Alaunos-Therapeutics-Announces-Poster-Presentation-at-the-American-Society-of-Clinical-Oncology-ASCO-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting2023-04-26T16:30:20Z<![CDATA[HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.]]>https://www.globenewswire.com/news-release/2023/03/30/2637502/0/en/Alaunos-Therapeutics-Appoints-Dr-Robert-J-Hofmeister-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors2023-03-30T11:00:40Z<![CDATA[Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy development Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy development]]>https://www.globenewswire.com/news-release/2023/03/29/2637202/0/en/Alaunos-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences-in-April.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April2023-03-29T21:30:13Z<![CDATA[HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.]]>https://www.globenewswire.com/news-release/2023/03/07/2621900/0/en/Alaunos-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html?f=22&fvtc=4&fvtv=14210Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results2023-03-07T12:00:43Z<![CDATA[HOUSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.]]>